FILING ANALYSIS · THURSDAY, OCTOBER 22
UTAH MEDICAL PRODUCTS INC UTMD — 8-K: Results of Operations and Financial Condition
neutral
UTMD's 3Q 2026 revenues were 12.1% lower than in 3Q 2025, and 9M 2026 revenues were 12.1% lower than in 9M 2025, due to lost sales from two major customers, partly offset by new biopharm sales and acquisition of Orion Medical Supplies Ltd, with net income increasing 6% in 3Q 2026 despite lower sales
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →